Sector News

Sanofi poaches AstraZeneca scientist as new research head

March 29, 2016
Life sciences

French drugmaker Sanofi has poached one of AstraZeneca’s top scientists to be its new research head in another high-profile departure for the British drugmaker.

Sanofi said on Tuesday that Yong-Jun Liu had been appointed as head of research with effect from April 1, reporting to Elias Zerhouni, the group’s president of global research and development.

Liu, a specialist in immunology with more than 250 published articles in leading academic journals, currently heads up research at AstraZeneca’s MedImmune biotechnology division, a position he has held since 2014.

Prior to that he led programmes at Baylor Research Institute and the MD Anderson Cancer Center, where he was founding director of the Cancer Immunology Research Institute.

His decision to leave AstraZeneca follows the exit last June of Briggs Morrison, the company’s former chief medical officer and head of late-stage drug development, and respiratory and inflammatory medicines head James Ward-Lilley.

AstraZeneca is going through a transition as older drugs lose patent protection and it invests heavily in new medicines, especially in the field of cancer immunotherapy.

It has a promising pipeline of experimental drugs but has also suffered some recent setbacks, including last week’s failure of its marketed heart drug Brilinta as a treatment for stroke patients and earlier disappointing results with a drug to treat lung and abdominal cancer mesothelioma.

Sanofi, meanwhile, is seeking to rejuvenate its early-stage pipeline and Zerhouni said Liu’s experience in immunology, oncology and translational medicine would be “vital assets” for this task.

By Ben Hirschler

Source: Reuters

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.